Halozyme Therapeutics Operating Chief Caudill to Exit

Dow Jones07-03
 
 

Halozyme Therapeutics Chief Operating Officer Cortney Caudill is leaving the biopharmaceutical company.

The company disclosed her departure in a Thursday filing with the Securities and Exchange Commission. It didn't provide a reason for her exit or share information about her successor.

The disclosure comes after the company on Tuesday said interim Chief Financial Officer David Ramsay had been promoted to the new role of president drug delivery.

 

Write to Elias Schisgall at elias.schisgall@wsj.com

 

(END) Dow Jones Newswires

July 02, 2026 16:24 ET (20:24 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment